The hemodynamic and nonhemodynamic crosstalk in cardiorenal syndrome type 1

CardioRenal Medicine

Volumn 4, Issue 2, 2014, Pages 103-112

  Virzì, Grazia Maria ^a,b,c   Clementi, Anna ^b,d   Brocca, Alessandra ^a,b   De Cal, Massimo ^a,b   Vescovo, Giorgio ^a   Granata, Antonio ^d   Ronco, Claudio ^a,b  

^a SAN BORTOLO HOSPITAL   (Italy)

^b International Renal Research Institute (IRRIV)   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d Azienda Ospedaliera San Giovanni di Dio   (Italy)

Author keywords

Acute kidney injury; Cardiorenal syndrome; Heart and renal dysfunction; Hemodynamic mechanisms; Organ crosstalk

Indexed keywords

CHEMOKINE; CYTOKINE;

APOPTOSIS; CARDIORENAL SYNDROME; CARDIOVASCULAR PARAMETERS; CELL DEATH; HEMODYNAMIC PARAMETERS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTRACELLULAR SIGNALING; MOLECULAR INTERACTION; NONHEMODYNAMIC PARAMETER; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 84907353290     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000362650     Document Type: Review

References (69)

1. Ledoux P: Cardiorenal syndrome (in undetermined language). Avenir Med 1951;48:149-153.
2. Molls RR, Rabb H: Limiting deleterious cross-talk between failing organs. Crit Care Med 2004;32 :2358-2359.
3. Viswanathan G, Gilbert S: The cardiorenal syndrome: makingthe connection. IntJ Nephrol 2011;2011:283-137.
4. Ronco C, Cicoira M, McCullough PA: Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kid ney dysfunction in the setting of acutely decompensated heart failure. JAm Coll Cardiol 2012; 60: 1031-1042.
5. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008;52: 1527-1539.
6. Bagshaw SM, Cruz DN, Aspromonte N, Dalie nto L, Ronco F, Sheinfeld G, Anker SD, Anand I, Bellomo R, Berl T, Bobek I, Davenport A, Haapio M, Hillege H, House A, Katz N, Maisel A, Mankad S, McCullough P, Mebazaa A, Palazzuoli A, Ponikowski P , Shaw A, Soni S, Vescovo G, Zamperetti N, Zanco P, Ronco C: Epidemiology of cardiorenal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 2010;25:1406-1416.
7. Cruz D N: Cardiorenal syndrome in critical care: the acute cardiorenal and renocardiac syndromes. Adv Chronic Kidney Dis 2013;20:56-66.
8. Haase M, Muller C, Damman K, Murray PT, Kellum JA, Ronc o C, McCullough PA: Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013;182:99-116.
9. Ismail Y, Kasmikha Z, Green HL, McCullough PA: Cardio-renal syndrome type 1: epidemiology, pathophysiology, and treatment. Semin Nephrol 2012;32:18-25.
10. Bozkurt B, Mann DL, Deswal A: Biomarkers of inflammation in heart failure. Heart Fail Rev 2010; 15:331-341.
11. Eren Z, Ozveren O, Buvukoner E, Kaspar E, Degertekin M, Kantarci G: A single- centre study of acute cardiorenal syndrome: incidence, risk factors and consequences. Cardiorenal Med 2012;2:168-176.
12. Fonarow GC,Stough WG,Abraham WT,Albert NM,Gheorghiade M,Greenberg BH,O'Connor CM,Sun JL,Yancy CW,Young JB: Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007; 50:768-777.
13. Bhandari S, Jam P: Management of acute coronary syndrome in chronic kidney disease. J Assoc Physicians India 2012;60:48-51.
14. Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Fang JC, Hernandez AF, Katz SD, Krishnamani R, Stough WG, Walsh MN, Butler J, Carson PE, Dimarco JP, Hershberger RE, Roge r s JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Starling RC: Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail 2013; 19:371-389.
15. Lazaros G, Tsiachris D, Tousoulis D, Patialiakas A, Dimitriadis K, Roussos D, Vergopoulos E, Tsioufis C, Vlachopoulos C, Stefanadis C: In-hospital worsening renal function is an independent pred ictor of one-year mortality in patients with acute myocardial infarction. IntJ Cardiol 2012; 155:97-101.
16. Amin AP, Sperms JA, Reid KJ, Lan X, Buchanan DM, Decker C, Masoudi FA: The prognostic importance ofworsening renal function during an acute myocardial infarction on long-term mortality. Am Heart J 2010;160: 1065- 1071.
17. Granfeldt A: Organ dysfunction following regional and global ischemia/reperfusion. Intervention with post-conditioning and adenocaine. Dan Med J 2012;59:B4496.
18. Hsieh ML Chen YC, Ch en CC, Wang CL, Wu LS, Wang CC: Renal dysfunction on admission, worsening renal function, and severity of acute kidney injury predict 2-year mortality in patients with acute myocardial infarction. Circ J 2013;77:217- 223.
19. Silverberg D, Wexler D, Slum M, Schwartz D, laina A: The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004; 13:163-170.
20. Cole RT, Masoumi A, Triposkiadis F, Giamouzis G, Georgiopoulou V, Kalogeropoulos A, Butler J: Renal dysfunction in heart failure. Med Clin North Am 2012;96:955-974.
21. Udani SM, Koyner JL: The effects of heart failure on renal function. Cardiol Clin 2010;28:453-465.
22. Ahmed A, Rich MW, Sanders PW, Perry GJ, Bakris GL, Zile MR, Love TE, Aban IS, Shlipak MG: Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol 2007; 99:393-398.
23. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B: The severe cardiorenal syndrome: ?Guyton revisited'. Eur Heart J 2005;26:11-17.
24. Packer M, Lee WH, Kessler PD: Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. Circulation 1986; 74:766-774.
25. Aspromonte N, Cruz DN, Valle R, Bonello M, Tubaro M, Gambaro G, Marchese G, Sant ini M, Ronco C: Metabolic and toxicological considerations for diuretic therapy in patients with acute heart failure. Expert Opin Drug Metab Toxicol 2011;7:1049-1063.
26. Aspromonte N, Cruz DN, V alle R, Ronco C: Management and monitoring of haemodynamic complications in acute heart failure. Heart Fail Rev 2011;16:575-581.
27. Ellison DH: Diuretic therapy and resistance in congestive heart failure. Cardiology 2001;96: 132-143.
28. McCullough PA: Contrast-induced acute kidney injury. JAm Coll Cardiol 2008;51:1419-1428.
29. Tumlin J, Stacul F, Ada m A, Becker CR, Davidson C, Lameire N, McCullough PA: Pathophysiology of contrast-induced nephropathy. AmJ Cardiol 2006;98:14K-20K.
30. Virzi GM, DayS, de Cal M, Vescovo G, Ronco C: Heart-kidney crosstalk and role of humoral signaling in critical illness. Crit Care 2014;18:201.
31. de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37.
32. White LE, Hassoun HT: Inflammatory mechanisms of organ crosstalk during ischemic acute kidney injury. mt J Nephrol 2012;2012:505197.
33. Chakraborti T, Mandal A, Mandal M, Das S, Chakraborti S: Complement activation in heart diseases. Role of oxidants. Cell Signal 2000; 12:607-617.
34. McElrath MJ,Steinman RM,Cohn ZA: Latent HIV-1 infection in enriched populations of blood monocytes and T cells from seropositive patients. J Clin Invest. 1991; 87:27-30.
35. Molitoris BA, Sutton TA: Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney mt 2004;66:496-499.
36. Vaduganathan M, Greene SJ, Butler J, Sabbah HN, Shantsila E, Lip GY, Gheorghiade M: The immunologi cal axis in heart failure: importance of the leukocyte differential. Heart Fail Rev 2013;18:835-845.
37. Coggins M, RosenzweigA: The fire within: cardiac inflammatory signaling in health and disease. Circ Res 2012; 110: 116- 12 5.
38. Frangogiannis NG: Regulation of the inflammatory response in cardiac repair. Circ Res 2012;110:159-173.
39. Wrigley BJ, Lip GY, Shant sila E: The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail 2011;13:1161-1171.
40. Satoh M, Minami Y, Takahashi Y, Nakamura M: Immune modulation: role of the inflammatory cytokine cascade in the failing human heart. Curr Heart Fail Rep 2008; 5:69-74.
41. VirzI GM, Torregrossa R, Cruz DN, Chionh CY, de Cal M, Soni SS, Dominici M, Vescovo G, Rosner MH, Ronco C: Cardiorenal syndrome type 1 may be immunologically mediated: a pilot evaluation of monocyte apoptosis. Cardiorenal Med 2012;2:33-42.
42. Benoist C, Mathis D: Mast cells in autoimmune disease. Nature 2002;420:875-878.
43. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL: Cytokines and cytokine receptors in advanced heart failure: a n analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103:2055-2059.
44. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK, Nordoy I, A ass H, Espevik T, Simonsen S, Froland SS, Gullestad L: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:376-382.
45. Amione P, Ricci E, Topo F, Izzo L, Pirovano R, Rega V, Cocci C, Masina M: Comparison of Allevyn Adhesive and Biatain Adhesive in the management of pressure ulcers. J Wound Care 2005; 14:365-370.
46. Ichimura T, Asseldonk EJ, Humphreys SD, Gunaratnam L, Duffield JS, Bonventre JV: Kidney injury molecule-i is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Inv est 2008; 118:1657-1668.
47. Yoshida M, Honma S: Regeneration of injured renal tubules. J Pharmacol Sci 2014;124:117-122.
48. Akcay A, Nguyen Q, Edelstein CL: Mediators of inflammation in acute kidney injury. Mediators Inflamm 2009; 2009:137072.
49. Li PL, Zhang Y: Cross talk between ceramide and redox signaling: implications for endothelial dysfunction and renal disease. Handb Exp Pharmacol 2013;216:171-197.
50. Khan SR: Stress oxidative: nephrolithiasis and chronic kidney diseases. Minerva Med 2013; 104:23-30.
51. Mandavia CR, Aroor AR, Demarco VG, Sowers JR: Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci 2013;92:601-608.
52. Gill R, Tsung A, Billiar T: Linking oxidative stress to inflammation: Toll-like receptors. Free Radic Biol Med 2010; 48 : 1121-1132.
53. Feltes CM, Van Eyk L Rabb R: Distant-organ changes afteracute kidney injury. Nephron Physiol 2008; l09:p80-p84.
54. Rubattu S, Mennuni S, Testa M, Mennuni M, Pierelli G, Pagliaro B, Gabriele E, Coluccia R, Autore C, Volpe M: Pathogenesis of chronic cardiorenal syndrome: is there a role for oxidative stress? mt j Mol Sci 2013; 14: 23011-23032.
55. Cohen JJ,Duke RC,Fadok VA,Sellins KS: Apoptosis and programmed cell death inimmunity.Annu Rev Immunol. 1992;0:267-293.
56. Norbury CL Rickson ID: Cellular responses to DNA damage. Annu Rev Pharmacol Toxicol 2001;41:367-401.
57. Mattson MP: Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000;1:120-129.
58. Solary E , Dubrez L, Eymin B: The role of apoptosis in the pathogenesis and treatment of diseases. Eur Respir J 1996;9:1293-1305.
59. Grams ME, Rabb R: The distant organ effects of acute kidney injury. Kidney mt 2012;81:942-948.
60. Ravasi A, Borkan SC: Apoptosis and acute kidney injury. Kidney mt 2011;80:29-40.
61. Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol 2007;35:495-516.
62. Ashkenazi A, DixitVM: Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11:255-260.
63. Thorburn A: Death receptor-induced cell killing. Cell Signal 2004; 16:139-144.
64. Sanz AS, Justo P, Sanchez-Nino MD, Blanco-Colio LM, Winkles JA, Kreztler M, Jakubowski A, Blanco J, Egido J, Ruiz-Ortega M, Ortiz A: The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 2008;19:695-703.
65. Misseri R, Meldrum DR, Dinarello CA, DagherP, Rile KL, Rink RC, Meldrum KK: TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol Renal Physiol 2005;28 8:F406-F411.
66. Ramar P, Song E, Kokeny G, ChenA, Ouyang N, LiebermanJ: Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci USA 2004;10 1:14883-14888.
67. Chandrashekhar Y, Sen S, Anway R, Shuros A, Anand I: Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodel ing in rats with myocardial infarction. JAm Coll Cardiol 2004;43:295-301.
68. Broberg CS, Sax BE, Okonko DO, Rampling MW, Bayne S, Rarries C, Davidson SJ, Uebing A, Khan AA, Them S, Gibbs JS, Burm an J, Gatzoulis MA: Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. JAm Coll Cardiol 2006;48:356-365.
69. Virzi GM, de Cal M, Cruz DN, Bolin C, Vescovo G, Ronco C: Type cardiorenal syndrome and its possible pathophysiological mechanisms (in Italian). G Ital Nefrol 2012;29:690-698.